A recent study found that patients receiving Daratumumab treatment may benefit from an alternative dosing technique of subcutaneous (SQ) administration vs. the traditional IV infusion.  Clinicians should be aware of advancing developments that have the potential to reduce the treatment burden and positively impact a patient’s quality of life. READ MORE HERE